December 2, 2011 — Lysosomal storage disorders such as Fabry's disease and Pompe's disease are much more common than previously thought, particularly atypical later-onset forms, a new study suggests.

Lysosomal dysfunction is common in neurodegenerative disease. Childhood lysosomal storage disorders are poised for gene therapy trials. Can scientists learn from them to develop Alzheimer’s therapies?

This new analysis shows early diagnosis of some lysosomal storage disorders can help avoid irreversible damage across the board. Lysosomal storage disorders (LSDs), including Gaucher disease (GD), ...

The Metabolic Disease Laboratory provides services for the diagnosis of lysosomal storage diseases. The laboratory provides screening of urine for glycosaminoglycans, oligosaccharides, sialic acid, ...

Main takeaways: Scientists at the Icahn School of Medicine at Mount Sinai in New York, the National Center for Advancing Translational Sciences (NCATS), and elsewhere have reversed the effects of ...

PUNE, MAHARASHTRA, INDIA, September 22, 2022 /EINPresswire.com/ -- The Global Lysosomal Storage Diseases Therapeutics Market reach USD 10.34 Billion in 2022 and is ...

A mutation in the CLCN6 gene is associated with a novel, particularly severe neurodegenerative disorder. Scientists have now analyzed the effect of a point mutation that was found in three unrelated ...